Cite
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
MLA
Nitin Jain, et al. “Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data.” Blood, vol. 140, Nov. 2022, pp. 234–37. EBSCOhost, https://doi.org/10.1182/blood-2022-170850.
APA
Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Marina Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado, Musa Yilmaz, Prithviraj Bose, … William G. Wierda. (2022). Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. Blood, 140, 234–237. https://doi.org/10.1182/blood-2022-170850
Chicago
Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, et al. 2022. “Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data.” Blood 140 (November): 234–37. doi:10.1182/blood-2022-170850.